Research & Development
Research & Development
Our Innovations
At Servier Pharmaceuticals, we are committed to making the world a better place for the patients we serve. Our research focuses on five key therapeutic areas: Oncology, Cardiology, Metabolism, Immune-Inflammatory and Neuroscience. Our extensive know-how and expertise position us to best address the unmet needs of patients. Servier draws on the excellence of its Research & Development (R&D) employees worldwide to develop effective treatment solutions.
Our Therapeutic Areas
Servier Pharmaceuticals is committed to reinvesting in research to help discover new treatments that improve our patients' lives. To fuel the next generation of discovery, we are reinvesting more of our total revenue back into our own R&D and innovative partnerships than into life-cycle management. We are not interested in investing in incremental projects but are looking to invest in the big advances that truly move the needle for our patients.
Oncology
According to the World Health Organization, cancer is the second leading cause of death worldwide, with one out of every six deaths stemming from cancer-related diseases. Cancer was also responsible for approximately 9.6 million deaths in 2018. We are targeting our oncology research on immuno-oncology, cellular metabolism, and apoptosis. Prioritized indications are hematological malignancies and solid tumors, such as gastrointestinal (colon, gastric and pancreas), breast and lung cancers, as well as cholangiocarcinoma and glioma.
Collaborations & Licenses
Our current collaborations and licenses include an emphasis on targeted protein degradation, epigenetic modifications, vectorization of BH3 mimetics, immuno-oncology modulators (small molecules, antibodies, IDH/MAT inhibitors) and CAR-T cell related technologies.
Partnerships
We are currently partnering with Allogene Therapeutics, Cellectis, Celsius, Institut Curie, IPSEN, Novartis, Pieris, Taiho Oncology, Vernalis, VHIO, and Walter and Eliza Hall Institute.
Cardiology
According to the World Health Organization, cardiovascular disease is the leading cause of death worldwide and responsible for 31 percent of deaths every year. We are targeting our cardiology research on heart failure and arrhythmias in general and specific populations.
Collaborations & Licenses
Our current collaborations and licenses include an emphasis on heart failure, atrial fibrillation, systemic hypertension, coronary artery diseases, arrhythmic cardiomyopathies, hyperlipidemia and venous diseases.
Partnerships
We are currently partnering with Amgen.
Metabolism
Based on data from the World Health Organization, the number of people with diabetes rose from 108 million in 1980 to 422 million in 2014. We are targeting our metabolic research on the treatment of type 2 diabetes and its complications, such as non-alcoholic steatohepatitis (NASH), diabetic kidney and liver disease. Our goal is to maintain a portfolio of drug discovery projects across several critical biological pathways implicated in disease progression and reversal.
Collaborations & Licenses
Our current collaborations and licensing deals include an emphasis on diabetic retinopathy and non-injectable insulins.
Partnerships
We are currently partnering with Harvard University and ScandiCure.
Immune-Inflammatory
According to the National Institute of Health, over 10 percent of immune-inflammatory diseases are severe and do not respond to any treatment. We are targeting our immune-inflammatory research on lupus, primary Sjögren's syndrome and systemic sclerosis as well as other chronic inflammatory and fibrotic diseases sharing similar pathophysiological mechanisms.
Collaborations & Licenses
Our current collaborations and licensing deals include an emphasis on autoimmune and fibrotic disorders.
Partnerships
We are currently partnering with Galapagos, ImmunoQure, and OSE Immunotherapeutics.
Neuroscience
Based on data from the World Health Organization, more than one billion people are affected by neurological disease worldwide. We are targeting our neuroscience research on proteinopathies, characterized by abnormal accumulation of specific proteins such as Parkinson’s disease, autism, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), Huntington's disease, and other rare diseases in neurodevelopmental and neurodegenerative disorders.
Collaborations & Licenses
Our current collaborations and licenses include an emphasis on sub-populations and rare forms of neurodegenerative disease.
Partnerships
We are currently partnering with Monash University, Neurochlore, Oncodesign, and Universitat Autonoma de Barcelona.
Therapies in development are being investigated for patient use and are not approved by the FDA.
More from Servier
Oncology Pipeline
We continue to build our treatment portfolio with a current focus on oncology within the United States. Globally, our pipeline includes a robust portfolio of treatments for various therapeutic areas.
Learn MoreClinical Trials
We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.
Learn MoreMedicines
Servier Pharmaceuticals' medicines change the lives of the patients we serve. Currently, within the United States, oncology treatment and care are our immediate focus.
Learn More